Department of Cardiology, Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, South China University of Technology, Guangzhou, 510080, China.
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China.
BMC Cardiovasc Disord. 2022 Jun 29;22(1):297. doi: 10.1186/s12872-022-02619-4.
The association between prothrombin time-international normalized ratio (PT-INR) and long-term prognosis among patients with coronary artery disease (CAD) without atrial fibrillation or anticoagulant therapy was still unclear. We analyzed the association of PT-INR levels and long-term mortality in a large cohort of CAD patients without atrial fibrillation or using of anticoagulant drugs.
We obtained data from 44,662 patients who were diagnosed with CAD and had follow-up information from January 2008 to December 2018. The patients were divided into 4 groups (Quartile 1: PT-INR ≤ 0.96; Quartile2: 0.96 < PT-INR ≤ 1.01; Quartile3: 1.01 < PT-INR ≤ 1.06; Quartile4: PT-INR > 1.06). The main endpoint was long-term all-cause death. Kaplan-Meier curve analysis and Cox proportional hazards models were used to investigate the association between quartiles of PT-INR levels and long-term all-cause mortality.
During a median follow-up of 5.25 years, 5613 (12.57%) patients died. We observed a non-linear shaped association between PT-INR levels and long-term all-cause mortality. Patients in high PT-INR level (Quartile4: PT-INR > 1.06) showed a significantly higher long-term mortality than other groups (Quartile2 or 3 or 4), (Compared with Quartile 1, Quartile 2 [0.96 < PT-INR ≤ 1.01], aHR = 1.00, 95% CI 0.91-1.00, P = 0.99; Quartile 3 [1.01 < PT-INR ≤ 1.06], aHR = 1.10, 95% CI 1.01-1.20, P = 0.03; Quartile 4 [PT-INR > 1.06], aHR = 1.33, 95% CI 1.22-1.45, P < 0.05).
Our study demonstrates high levels of PT-INR were associated with an increased risk of all-cause mortality.
在没有房颤或抗凝治疗的冠心病(CAD)患者中,凝血酶原时间国际标准化比值(PT-INR)与长期预后之间的关系尚不清楚。我们分析了在一个大型 CAD 患者队列中,无房颤或使用抗凝药物的患者中 PT-INR 水平与长期死亡率的关系。
我们从 2008 年 1 月至 2018 年 12 月接受 CAD 诊断并有随访信息的 44662 名患者中获得数据。患者被分为 4 组(第 1 四分位数:PT-INR≤0.96;第 2 四分位数:0.96<PT-INR≤1.01;第 3 四分位数:1.01<PT-INR≤1.06;第 4 四分位数:PT-INR>1.06)。主要终点是长期全因死亡。Kaplan-Meier 曲线分析和 Cox 比例风险模型用于研究 PT-INR 水平四分位与长期全因死亡率之间的关系。
在中位数为 5.25 年的随访期间,有 5613 名(12.57%)患者死亡。我们观察到 PT-INR 水平与长期全因死亡率之间存在非线性关系。高 PT-INR 水平组(第 4 四分位数:PT-INR>1.06)的长期死亡率明显高于其他组(第 2 或 3 或 4 四分位数)(与第 1 四分位数相比,第 2 四分位数[0.96<PT-INR≤1.01],aHR=1.00,95%CI 0.91-1.00,P=0.99;第 3 四分位数[1.01<PT-INR≤1.06],aHR=1.10,95%CI 1.01-1.20,P=0.03;第 4 四分位数[PT-INR>1.06],aHR=1.33,95%CI 1.22-1.45,P<0.05)。
我们的研究表明,高 PT-INR 水平与全因死亡率增加相关。